lu 135252 has been researched along with thromboxane b2 in 1 studies
Studies (lu 135252) | Trials (lu 135252) | Recent Studies (post-2010) (lu 135252) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
---|---|---|---|---|---|
196 | 13 | 14 | 7,483 | 715 | 485 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Janzen, R; Koch, T; Münter, K; Neuhof, H; Schmeck, J | 1 |
1 other study(ies) available for lu 135252 and thromboxane b2
Article | Year |
---|---|
Endothelin-1 and thromboxane A2 increase pulmonary vascular resistance in granulocyte-mediated lung injury.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Animals; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Female; Granulocytes; In Vitro Techniques; Male; N-Formylmethionine Leucyl-Phenylalanine; Perfusion; Phenylpropionates; Prospective Studies; Pulmonary Artery; Pyrimidines; Rabbits; Random Allocation; Respiratory Distress Syndrome; Thromboxane A2; Thromboxane B2; Vascular Resistance | 1998 |